Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Investor webinar 3pm AEST Tuesday 2 July

Thursday, June 27, 2024 1 min read
Key Takeaway: Radiopharm Theranostics is hosting an investor webinar on July 2, 2024, at 3 PM AEST. The company has recently made significant strides, including receiving IND approval from the US FDA for a Phase I therapeutic clinical study targeting B7H3 with BetaBart (RV-01). This proactive approach aims to keep investors informed about ongoing developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Investor webinar scheduled for July 2, 2024, indicating proactive engagement.
  • Radiopharm Theranostics has received IND approval from the FDA.
  • Positive clinical updates across four programs highlight progress.

Full Press Release Details

• Announcements
• June 27, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• June 30, 2023
• Announcements
• October 18, 2023
• Updates
• March 13, 2024
• Announcements
• April 12, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

When is the investor webinar for RADX?

The investor webinar is scheduled for July 2, 2024, at 3 PM AEST.

What recent approval did Radiopharm receive?

Radiopharm Theranostics received IND approval from the US FDA for a Phase I study.

What is the focus of the BetaBart study?

The BetaBart (RV-01) study targets B7H3 in a therapeutic clinical setting.

What updates has Radiopharm provided recently?

Radiopharm has shared positive clinical updates across four programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics investor webinar clinical updates FDA approval
Last updated: Jun 27, 2024